Starling Oncology, Inc. (STLN)
Nasdaq · Services-Offices & Clinics Of Doctors Of Medicine · Services · CIK 1799191 · fiscal year ends in Dec
Closing price $6.63 on 29 Oct 2026; 52-week range $2.38 to $7.05.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $587.2M
- Revenue growth
- 38.4%
- Net income, last twelve months
- -$36.3M
- Earnings per share
- -$0.28
- Operating margin
- -4.4%
- Net margin
- -6.2%
- Free cash flow
- -$3.3M
- Market value
- $666.6M
- Cash
- $41.1M
- Debt
- $79.9M
- Shares outstanding
- 100.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $502.7M | -$36.1M | -$60.6M | -$0.54 | -$27.8M | 10-K filed 12 Mar 2026 |
| FY2024 | 31 Dec 2024 | $393.4M | -$60.1M | -$64.7M | -$0.71 | -$30.3M | 10-K filed 26 Mar 2025 |
| FY2023 | 31 Dec 2023 | $324.2M | -$77.0M | -$83.1M | -$0.92 | -$40.9M | 10-K filed 28 Mar 2024 |
| FY2022 | 31 Dec 2022 | $252.5M | -$82.0M | $152.0K | -$0.21 | -$67.3M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $203.0M | -$45.9M | -$10.9M | -$0.16 | -$35.5M | 10-K filed 11 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $161.3M | -$9.8M | -$0.08 |
| Q1 FY2026 | 31 Mar 2026 | $147.4M | -$2.5M | -$0.02 |
| Q4 FY2025 | 31 Dec 2025 | $142.0M | -$7.5M | -$0.04 |
| Q3 FY2025 | 30 Sep 2025 | $136.6M | -$16.5M | -$0.14 |
| Q2 FY2025 | 30 Jun 2025 | $119.8M | -$17.0M | -$0.15 |
| Q1 FY2025 | 31 Mar 2025 | $104.4M | -$19.6M | -$0.21 |
| Q4 FY2024 | 31 Dec 2024 | $100.3M | -$13.2M | -$0.14 |
| Q3 FY2024 | 30 Sep 2024 | $99.9M | -$16.1M | -$0.18 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Specialty pharmacy | $269.2M | 53.5% |
| Patient services | $229.0M | 45.5% |
| Clinical trials & other | $4.6M | 0.9% |
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Specialty pharmacy | $269.2M | 53.5% |
| FFS revenue | $148.5M | 29.5% |
| Capitated revenue | $80.5M | 16.0% |
| Clinical trials & other | $4.6M | 0.9% |
Company events
The newest 8-K filings of 82 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 2 Sep 2026 | 8-K | Leadership change | 5.02 |
| 21 Aug 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Aug 2026 | 8-K | Bylaws or fiscal year change, Investor update | 5.03, 7.01, 9.01 |
| 7 Jul 2026 | 8-K | Material agreement, New debt, Share sale, Investor update | 1.01, 2.03, 3.02, 7.01, 9.01 |
| 18 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 22 May 2026 | 8-K | Cybersecurity incident | 1.05, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 12 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Feb 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 192 held.
| Filed | Form | Period |
|---|---|---|
| 2 Sep 2026 | 8-K | 1 Sep 2026 |
| 21 Aug 2026 | 8-K | 20 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 3 Aug 2026 | 8-K | 28 Jul 2026 |
| 7 Jul 2026 | 8-K | 1 Jul 2026 |
| 18 Jun 2026 | 8-K | 17 Jun 2026 |
| 22 May 2026 | 8-K | 20 May 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 17 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 21 Aug 2026 | Hively Brad, Director | Sale under a trading plan | 298,853 | $6.51 | $1.9M | 411,976 | 24 Aug 2026 |
| 14 Aug 2026 | Chernett Jorey, 10% owner | Purchase | 12,000 | $6.54 | $78.5K | 10,660,858 | 17 Aug 2026 |
| 21 Jul 2026 | Chernett Jorey, 10% owner | Purchase | 18,000 | $5.27 | $94.9K | 10,648,858 | 22 Jul 2026 |
| 14 Jul 2026 | Podnos Yale, Chief Medical Officer | Sale under a trading plan | 17,974 | $6.43 | $115.6K | 259,527 | 16 Jul 2026 |
| 14 Jul 2026 | Podnos Yale, Chief Medical Officer | Sale under a trading plan | 5,478 | $6.35 | $34.8K | 259,527 | 16 Jul 2026 |
| 10 Jul 2026 | Chernett Jorey, 10% owner | Purchase | 15,000 | $5.85 | $87.8K | 10,630,858 | 13 Jul 2026 |
| 23 Jun 2026 | Chernett Jorey, 10% owner | Purchase | 18,000 | $5.02 | $90.4K | 10,615,858 | 24 Jun 2026 |
| 8 Jun 2026 | Podnos Yale, Chief Medical Officer | Sale under a trading plan | 23,451 | $5.38 | $126.1K | 259,527 | 9 Jun 2026 |
| 4 Jun 2026 | Chernett Jorey, 10% owner | Purchase | 12,000 | $4.75 | $57.0K | 10,579,858 | 5 Jun 2026 |
| 20 May 2026 | Chernett Jorey, 10% owner | Purchase | 33,500 | $4.07 | $136.3K | 10,567,858 | 21 May 2026 |
| 19 May 2026 | Chernett Jorey, 10% owner | Purchase | 5,000 | $4.05 | $20.3K | 10,534,358 | 21 May 2026 |
| 19 May 2026 | Chernett Jorey, 10% owner | Purchase | 30,000 | $4.09 | $122.7K | 10,529,358 | 20 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 21 Aug 2026 | BRADFORD HIVELY, Director | 298,853 | $2.0M | 21 Aug 2026 |
| 14 Jul 2026 | YALE PODNOS, Officer | 23,452 | $146.6K | 14 Jul 2026 |
| 8 Jun 2026 | YALE PODNOS, Officer | 23,451 | $114.2K | 8 Jun 2026 |
| 14 Apr 2026 | MOHIT KAUSHAL, Director | 95,719 | $315.9K | 14 Apr 2026 |
| 15 Dec 2025 | BRADFORD DANIEL HIVELY, Director | 13,333 | $50.3K | 15 Dec 2025 |
| 18 Nov 2025 | MARK PACALA, Director | 50,000 | $200.0K | 18 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 May 2026 | M33 Growth I L.P. | 13D amended | 4.94% | 5.0M |
| 16 Mar 2026 | Chernett Jorey | 13G amended | 10.2% | 10.1M |
| 15 Jan 2026 | Chernett Jorey | 13G | 5.2% | 5.1M |
| 20 Nov 2025 | M33 Growth I LP | 13D amended | 5.46% | 6.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.5M | -3.79% | 5.62 |
| 30 Sep 2026 | 6.8M | -3.7% | 4.31 |
| 15 Sep 2026 | 7.1M | +3.48% | 7.35 |
| 31 Aug 2026 | 6.8M | -0.98% | 5.58 |
| 14 Aug 2026 | 6.9M | -3.78% | 3.51 |
Funds that hold it
From each fund's latest Form 13F.
140 funds held it at 30 Jun 2026: 77 added and 25 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 4,749,030 | $25.8M | +333,163 |
| Deerfield Management Company, L.P. | 3,360,052 | $18.2M | 0 |
| Vanguard Capital Management LLC | 3,265,531 | $17.7M | -211,250 |
| Josh Arnold Investment Consultant, LLC | 2,464,359 | $13.4M | 0 |
| Geode Capital Management, LLC | 1,899,998 | $10.3M | +142,151 |
| Goldman Sachs Group Inc. | 1,735,337 | $9.4M | +383,438 |
| Wexford Capital LP | 1,711,323 | $9.3M | 0 |
| State Street Corp. | 1,552,917 | $8.4M | +91,463 |
| Nuveen, LLC | 1,408,720 | $7.6M | +1,313,456 |
| Renaissance Technologies LLC | 1,365,913 | $7.4M | +463,104 |
Peers
Companies in the same industry.
- Hims & Hers Health, Inc. (HIMS): revenue $2.6B, market value $6.9B
- Teladoc Health, Inc. (TDOC): revenue $2.5B, market value $1.6B
- SBC Medical Group Holdings Inc. (SBC): revenue $175.2M, market value $582.6M